Barclays’s Bristol-Myers Squibb BMY Stock Holding History

Barclays’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.35M	Buy	137,600 +80,000	+139%	+$4.66M	﹤0.01%	1550
2025 Q4	$3.11M	Buy	57,600 +20,300	+54%	+$977K	﹤0.01%	2611
2025 Q3	$1.68M	Buy	37,300 +8,100	+28%	+$378K	﹤0.01%	3004
2025 Q2	$1.35M	Buy	+29,200	New	+$1.43M	﹤0.01%	3128
2025 Q1	–	Sell	-71,500	Closed	-$4.04M	–	5280
2024 Q4	$4.04M	Hold	71,500	–	–	﹤0.01%	2351
2024 Q3	$3.7M	Sell	71,500 -38,800	-35%	-$1.82M	﹤0.01%	2342
2024 Q2	$4.58M	Sell	110,300 -41,200	-27%	-$1.84M	﹤0.01%	1603
2024 Q1	$8.22M	Buy	151,500 +146,000	+2,655%	+$7.44M	﹤0.01%	1535
2023 Q4	$282K	Sell	5,500 -34,500	-86%	-$1.81M	﹤0.01%	4257
2023 Q3	$2.32M	Buy	+40,000	New	+$2.45M	﹤0.01%	1799
2023 Q1	–	Sell	-425,000	Closed	-$30.6M	–	5103
2022 Q4	$30.6M	Buy	+425,000	New	+$32M	0.01%	693
2022 Q1	–	Sell	-50,000	Closed	-$3.12M	–	4976
2021 Q4	$3.12M	Buy	+50,000	New	+$2.93M	﹤0.01%	2067
2021 Q1	–	Sell	-741,200	Closed	-$46M	–	4709
2020 Q4	$46M	Sell	741,200 -8,500	-1%	-$523K	0.02%	482
2020 Q3	$45.2M	Buy	749,700 +469,900	+168%	+$28.3M	0.03%	426
2020 Q2	$16.5M	Sell	279,800 -251,800	-47%	-$15.1M	0.01%	727
2020 Q1	$29.6M	Sell	531,600 -193,400	-27%	-$11.8M	0.02%	485
2019 Q4	$46.5M	Sell	725,000 -228,200	-24%	-$13.1M	0.03%	538
2019 Q3	$48.3M	Buy	953,200 +149,400	+19%	+$7.02M	0.03%	481
2019 Q2	$36.5M	Sell	803,800 -1,197,000	-60%	-$55.8M	0.02%	613
2019 Q1	$95.5M	Buy	2,000,800 +1,530,800	+326%	+$76.3M	0.07%	249
2018 Q4	$24.4M	Sell	470,000 -22,400	-5%	-$1.2M	0.02%	657
2018 Q3	$30.6M	Sell	492,400 -55,600	-10%	-$3.3M	0.02%	639
2018 Q2	$30.3M	Sell	548,000 -356,200	-39%	-$19.2M	0.03%	579
2018 Q1	$57.2M	Sell	904,200 -149,500	-14%	-$9.62M	0.04%	372
2017 Q4	$64.6M	Buy	1,053,700 +550,600	+109%	+$34.4M	0.05%	305
2017 Q3	$32.1M	Buy	503,100 +115,400	+30%	+$6.74M	0.03%	475
2017 Q2	$21.6M	Sell	387,700 -44,500	-10%	-$2.42M	0.02%	569
2017 Q1	$23.5M	Sell	432,200 -555,500	-56%	-$30.5M	0.03%	503
2016 Q4	$57.7M	Buy	987,700 +695,300	+238%	+$38M	0.06%	244
2016 Q3	$15.8M	Buy	292,400 +176,500	+152%	+$11.3M	0.02%	644
2016 Q2	$8.53M	Sell	115,900 -138,600	-54%	-$9.79M	0.01%	929
2016 Q1	$16M	Sell	254,500 -112,900	-31%	-$7.12M	0.02%	563
2015 Q4	$25M	Sell	367,400 -228,300	-38%	-$15.1M	0.03%	496
2015 Q3	$35.1M	Buy	595,700 +111,500	+23%	+$7.07M	0.04%	374
2015 Q2	$32M	Sell	484,200 -142,800	-23%	-$9.41M	0.04%	446
2015 Q1	$40.1M	Buy	627,000 +150,300	+32%	+$9.41M	0.05%	394
2014 Q4	$28.1M	Buy	476,700 +189,200	+66%	+$10.7M	0.03%	589
2014 Q3	$14.7M	Sell	287,500 -71,200	-20%	-$3.56M	0.01%	911
2014 Q2	$17.2M	Sell	358,700 -907,800	-72%	-$44.7M	0.02%	788
2014 Q1	$64.6M	Buy	1,266,500 +278,800	+28%	+$14.8M	0.07%	234
2013 Q4	$52.3M	Sell	987,700 -641,800	-39%	-$32.7M	0.05%	326
2013 Q3	$75M	Buy	1,629,500 +153,600	+10%	+$6.74M	0.09%	187
2013 Q2	$66M	Buy	+1,475,900	New	+$64.1M	0.08%	190

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's BMY Position: Q1 2026 in Review

Barclays reduced its Bristol-Myers Squibb (BMY) stake by 26% in Q1 2026, selling an estimated $111M and leaving 5,419,207 shares worth $329M. The position accounts for 0.08% of the portfolio, ranked #189.

Barclays first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $511M in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Barclays held 5,419,207 shares of Bristol-Myers Squibb worth $329M as of Q1 2026.
Barclays sold 1,899,064 Bristol-Myers Squibb shares in Q1 2026, an estimated $111M.
Bristol-Myers Squibb made up 0.08% of Barclays's portfolio in Q1 2026, its #189 holding.
Barclays first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
Barclays's Bristol-Myers Squibb position peaked at $511M in Q1 2025.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.